Prenatal Testing

cfDNA Screening Shows High Accuracy for Fetal Risk Without Partner Testing

A multi-site study found cfDNA screening achieves 94.4% sensitivity for fetal risk assessment without partner testing, supporting its routine use in general-risk pregnancies.

Prenatal Testing

NIH Study Links Abnormal Prenatal DNA Tests to Cancer Detection

NIH researchers found undetected cancers in nearly half of pregnant people with abnormal prenatal cfDNA test results.

Prenatal Testing

Natera Acquires Reproductive Health Assets from Invitae

Natera has acquired certain assets from Invitae relating to its non-invasive prenatal screening and carrier screening business.

Juno Hazel Increases Accessiblity of Non-Invasive Prenatal Screening

Nov 18, 2022 | Prenatal Testing

Juno Diagnostics has announced the launch of Juno Hazel, a non-invasive prenatal screening (NIPS) solution.

Sera Prognostics Predicts Clinical Utility of Preterm Test-and-Treat Strategies

Nov 16, 2022 | Prenatal Testing

Sera Prognostics’ blood-based test offers individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.

Biomarkers Could Point to Preclampsia Risk

Nov 11, 2022 | Prenatal Testing

Cedars-Sinai investigators have found that a specific imbalance of two placental proteins could predict preeclampsia risk.

Fetal Fraction Enrichment for NIPT

Oct 10, 2022 | Prenatal Testing

Diagnostic screening for Down’s Syndrome during pregnancy was difficult until the development of an NIPT fetal fraction test.

Biomarker Panel May Help Predict Gestational Diabetes Early in Pregnancy

May 27, 2022 | Diabetes & Metabolic Diseases, Prenatal Testing

Researchers may have identified an effective way of detecting gestational diabetes mellitus (GDM) earlier in pregnancy.

Sera Prognostics’ Data Shows Benefit of Preterm Birth Risk Assessment Tool

May 24, 2022 | Prenatal Testing

Sera Prognostics, a company focused on curbing preterm birth risks, demonstrated data on the health and economic benefits of its PreTRM test.

FDA Warns of Risks Associated with Non-Invasive Prenatal Screening Tests

Apr 22, 2022 | Prenatal Testing

The FDA is warning the public of the risk of false results, inappropriate use, and inappropriate interpretation of results with NIPS tests.

Machine Learning Helps Predict Postpartum Hemorrhage Risk

Nov 9, 2021 | Prenatal Testing

Sema4 and Mount Sinai collaborated on two studies that demonstrate how machine learning can be used to improve postpartum hemorrhage risk prediction.

New Testing Device Helps Identify Risk for Preterm Birth

Oct 13, 2021 | Mass Spectrometry Instruments, Prenatal Testing

Researchers have developed a testing device that may help advance diagnosis and treatment of preterm birth.

Prenatal Test Developed for At-Risk Pregnancies

Oct 6, 2021 | Molecular Diagnostics, Prenatal Testing

Veritas has created a new prenatal diagnostic test that can help identify fetal anomalies in at-risk pregnancies.

Biomarkers Id’d that May Detect Pregnancy Risks Earlier

Sep 24, 2021 | Prenatal Testing

Researchers have identified biological markers that could improve blood tests of pregnant women to detect risks of pregnancy complications earlier.

BioFluidica to Commericalize LiquidScan Biopsy System

Sep 21, 2021 | Leukemia, Microbiology Instruments, Prenatal Testing

BioFluidica, a privately held biotechnology company, plans to commercialize its LiquidScan Automated Liquid Biopsy System.

Portfolio of Reproductive Information-Driven Genomic Solutions Introduced

Sep 9, 2021 | Fertility Testing, Prenatal Testing

Sema4 Elements, a portfolio of information-driven genomic reproductive health solutions that enable providers to treat patients holistically, has launched.